Article Information
- Received September 9, 2004
- Revision received December 28, 2004
- Accepted December 30, 2004
- First published February 23, 2005.
- Version of record published February 23, 2005.
Author Information
Author contributions
Disclosures
- Received September 9, 2004.
- Revision received December 28, 2004.
- Accepted December 30, 2004.
This work was supported by Grants SAF 2002-01566 (M.L.C) and SAF 2003-00745 (M.G.) from the Spanish Ministry of Science and Technology, Grant CAM 08.1/0079 from the Community of Madrid (M.G., M.L.C.), Red de Investigación de Enfermedades Neurológicas (M.L.C.), and Fundación Científica de la Asociación Española contra el Cáncer (M.G.). B.G.R. is the recipient of a fellowship from the Community of Madrid. We thank Dr. K. Mackie for anti-CB1 antibody and CB1 and CB2 antigenic peptides, Dr. J. Rodrigo for anti-N-Tyr antibody, and Sanofi-Synthelabo for SR141716 and SR144528. Dr. I. Ferrer is acknowledged for helpful discussions, Dr. L. López-Mascaraque for assistance in microscopic imaging, and M. E. Fernández de Molina for excellent technical assistance.
Correspondence should be addressed to Dr. María L. de Ceballos, Neurodegeneration Group, Cajal Institute, Consejo Superior de Investigaciones Científicas, Avenida Doctor Arce, 37, 28002 Madrid, Spain. E-mail: mceballos{at}cajal.csic.es.
Copyright © 2005 Society for Neuroscience 0270-6474/05/251904-10$15.00/0
Online Impact